Dishman Carbogen Amcis: Your One-Stop Global CRAMS Partner
Introduction To Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd., also known as DCAL, is a global pharmaceutical company that specialises in Contract Research and Manufacturing Services, commonly referred to as CRAMS. With operations spanning six countries, the company offers a full range of pharmaceutical services, from early-stage drug development to commercial-scale manufacturing.
DCAL operates through two main business segments. The first is CRAMS, which contributes around 75 percent of its total revenue. This includes molecule development, production of clinical trial materials, and long-term manufacturing partnerships. A major share of this business comes from Carbogen Amcis in Switzerland, which alone accounts for nearly half of DCAL’s revenue. The second segment, Marketable Molecules, contributes the remaining 25 percent and focuses on specialty chemicals, disinfectants, cholesterol and vitamin D analogues, and generic active pharmaceutical ingredients.
DCAL has built a strong global presence with 25 multipurpose manufacturing sites located across India, Switzerland, the Netherlands, France, the United Kingdom, and China. It also operates seven international sales offices to serve its wide client base. While the European facilities are currently operating at around 80 percent capacity, the Indian units are running at about 30 percent, leaving significant room for growth, especially after recent regulatory clearance at the Bavla plant in Gujarat. DCAL’s consistent focus on quality, its ability to manage complex chemical processes, and its reliable service have made it a preferred partner for many global pharmaceutical leaders.
Its client list includes companies such as Novartis, Takeda, Eisai, Johnson and Johnson, and Seagen. With an order book of about 1,250 crore rupees and 14 molecules in advanced Phase III trials, DCAL is well placed for future growth in the pharmaceutical manufacturing space.
Board Of Directors Of Dishman Carbogen Amcis Limited
Here is the list of the Board of Directors of Dishman Carbogen Amcis Limited, along with their designations:
1. Mr. Janmejay R. Vyas – Chairman
2. Mrs. Deohooti J. Vyas – Whole-time Director
3. Mr. Arpit J. Vyas – Global Managing Director
4. Mr. Hemant J. Bhatt – Director
5. Dr. Margie S. Parikh – Director
6. Mr. Kulin N. Shah – Director
Source: Dishman Carbogen Amcis Ltd.1
Products Offered By Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd. (DCAL) offers a diverse range of products and services tailored to the pharmaceutical, healthcare, and personal care industries. Their offerings span from chemical development to the commercial manufacture and supply of active pharmaceutical ingredients (APIs), with a strong emphasis on quality, innovation, and regulatory compliance.
1. Health and Personal Care Solutions
DCAL is a globally recognised developer and producer of high-purity APIs for the pharmaceutical and personal care industries. Their products are manufactured at GMP and FDA-inspected facilities, ensuring compliance with international standards. Key offerings include antimicrobial agents like Octenidine HCl, Cetrimide powder, and Benzalkonium Chloride (BKC) 50%, which are effective against major pathogens, including MRSA.
These products are used as antiseptics for skin and mucous membranes, disinfectants for surgical procedures, and preservatives in oral care products, body lotions, and other topical applications.
2. Vitamin D Analogues and Soft Gel Capsules
With over four decades of experience, DCAL has established itself as a leader in the production of cholesterol and Vitamin D analogues. Their integrated manufacturing units in India and Europe produce a wide spectrum of Vitamin D3 products for pharmaceutical, nutraceutical, and animal nutrition applications. The product range includes:
- Vitamin D3 capsules – 1000, 2000, 5000, 10,000, 50,000, and 60,000 IU strengths
- Calcitriol capsules – 0.25 mcg and 0.50 mcg
- Alfacalcidol capsules – 0.25 mcg, 0.50 mcg, and 1 mcg
- Calcifediol capsules – 30 mg and 60 mg
- Vitamin E capsules – 200 mg and 400 mg
These products are developed using advanced technologies and are supported by comprehensive regulatory documentation.
3. Niche APIs For Pharmaceutical Industries
DCAL has developed and manufactured several niche and high-value generic APIs in specific therapeutic fields. Their product portfolio focuses on complex intermediates and APIs covering therapeutic areas such as anaesthetics, contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes.
With facilities approved by globally recognised health agencies, DCAL ensures regulatory compliance and offers worldwide distribution in both regulated and semi-regulated markets.
4. Quaternary Salts
DCAL's portfolio includes over 20 multifunctional quaternary ammonium compounds (Quats) like Tetrabutylammonium Bromide (TBAB), Pentyltrimethylammonium Chloride (PTMAC), and Cetyltrimethylammonium Bromide (CTAB). These compounds find applications as phase transfer catalysts, pharmaceutical intermediates, antistatic agents, agrochemicals, polymers and plastics, painting industries, oilfield auxiliaries, electronic industries, flavours and fragrances, and cosmetics.
Many of these Quats exhibit excellent antimicrobial properties, making them suitable for use in household cleaning products and disinfectants.
5. Encapsulation Capabilities
DCAL offers advanced encapsulation technologies that enhance the efficacy and safety of disinfectants and antiseptics. For instance, encapsulated Benzalkonium Chloride (BKC) forms a thin, invisible film on hard surfaces, retaining disinfectant properties and releasing the active ingredient upon contact with moisture.
This technology results in products that are skin-friendly, alcohol-free, provide long-lasting protection, and are safer to handle. Applications include personal care products, surface disinfectants, and antimicrobial cleaning solutions.
Source: Dishman Carbogen Amcis.2
Dishman Carbogen Amcis Ltd. Customer Care
For any sales related queries or support, Dishman’s customer care team is here to help. You can reach them at +91 2717 420134 or email: dishman@dishmangroup.com.
Trusted Partner In Complex Drug Development
Dishman Carbogen Amcis Ltd. (DCAL) stands out as a fully integrated, end-to-end Contract Research and Manufacturing Services (CRAMS) provider, offering a seamless solution for pharmaceutical companies from early-stage research to commercial-scale production. What truly sets DCAL apart is its ability to handle complex, high-value molecules across multiple geographies, supported by a global network of 25 multipurpose manufacturing facilities and 7 sales offices spread across India, Europe, and China.
DCAL’s strength lies in its deep scientific expertise, regulatory accreditations across major markets such as the US, EU, Japan and WHO, and its long-standing partnerships with leading global pharma companies. Whether it’s early-stage molecule development, clinical trial material supply, or full-scale commercial production, DCAL ensures consistency, compliance, and quality at every step. This one-stop approach not only simplifies the drug development journey for its clients but also makes DCAL a trusted and strategic partner in the global pharmaceutical supply chain.
Also Read: Moneyboxx Finance: Tailored MSME Lending With Tech-Driven Edge
Key Strengths Of Disman Carbogen Amcis Ltd.
Key Strengths of Dishman Carbogen Amcis Ltd. (Simplified)
1. Strong Global Position in CRAMS (Contract Research and Manufacturing Services)
DCAL is one of the few companies in the world that can handle the entire process of developing and manufacturing pharmaceutical products, from early research to commercial production. With manufacturing units across the globe and approvals from major international regulators, DCAL is well-positioned to serve big pharma companies.
It can handle complex and high-value drug development projects in multiple countries, making it a reliable and strategic partner for some of the world's leading pharmaceutical firms.
2. Long-Term Contracts Provide Steady Income
Once DCAL helps a client take a drug into full commercial production, they usually sign long-term contracts. These agreements give DCAL steady and predictable revenue over time. Because these drugs are difficult to switch suppliers for, clients tend to stick with DCAL, which improves customer loyalty and helps the company maintain consistent earnings.
3. Big Investments to Grow in the High-Profit Oncology Market
Since FY20, DCAL has invested INR 1,555 Cr to expand its capacity, especially in the high-growth oncology (cancer treatment) segment. This includes setting up a new injectable drug facility in France. In addition, the recent regulatory approval for its Bavla site puts DCAL in a strong position to win new contracts for manufacturing high-margin drugs from global pharmaceutical innovators.
4. Profit Margins Are Improving Due to Better Product Mix
DCAL’s EBITDA margin, essentially its operating profit percentage—rose from 11.0% in FY24 to 15.9% in the first nine months of FY25. This improvement came from focusing on more profitable products, cutting costs, and lower losses due to currency exchange rates.
Management is aiming for even higher EBITDA margins of 17.0-18.0% in FY25. If achieved, this would strengthen the company’s financial health significantly.
5. High-Profile Clients and a Strong Product Pipeline
DCAL works with some of the biggest names in the pharmaceutical industry, including Novartis, Johnson & Johnson, Seagen, and Eisai. The company is currently involved in the development of over 500 different drug molecules.
This includes 14 drugs that are in the final stages (Phase III) of clinical trials. DCAL also has a strong order pipeline worth around INR 1,250 Cr, which signals promising growth ahead.
6. Stable Financial Backing from Leading Banks
As of September 2024, DCAL had a total debt of INR 2,165 Cr and net debt of INR 1,773 Cr. Its debt-to-equity ratio stands at a manageable 0.4x, and its debt is 21% of its total assets—both considered healthy levels.
The company is backed by top financial institutions such as Credit Suisse, ABN Amro, SBI, Bank of Baroda, Union Bank of India, Indian Bank, IDFC Bank, and Axis Bank.
7. Trusted by Global Regulators
DCAL’s manufacturing sites have approvals from top regulatory bodies like the USFDA (United States), EDQM (Europe), PMDA (Japan), Swissmedic (Switzerland), and WHO (World Health Organization).
The company recently resolved a regulatory issue at its Bavla site, and its continued investments in compliance show a strong commitment to quality, safety, and operational excellence.
Financial Snapshot Dishman Carbogen Amcis Ltd.
Source: Source: audited financials, credit rating reports
To arrange the capital, Dishman Carbogen Amcis Ltd. also offers corporate bonds. These opportunities from the company are secured and are rated by credit rating agencies. On Grip Invest, investors invested in CREDIT ‘A+’ rated bonds of the company that offered fixed returns of up to 11.1%. To invest in similar, rated, regulated and secured fixed-income opportunities sign-up for Grip Invest today and start earning fixed returns:
References:
1. Dishman Carbogen Amcis Ltd., accessed from: https://imdcal.com/about-us/leadership-team
2. Dishman Carbogen Amcis Ltd., accessed from: https://imdcal.com/what-we-do/products
Want to stay at the top of your finances?
Join the community of 4 lakh+ investors and learn more about Grip Invest, the latest financial knick-knacks, and shenanigans in the world of investing.
Happy Investing!
Disclaimer - Investments in debt securities/municipal debt securities/securitised debt instruments are subject to risks including delay and/ or default in payment. Read all the offer related documents carefully. The investor is requested to take into consideration all the risk factors before the commencement of trading.
This communication is prepared by Grip Broking Private Limited (bearing SEBI Registration No. INZ000312836 and NSE ID 90319) and/or its affiliate/ group company(ies) (together referred to as “Grip”) and the contents of this disclaimer are applicable to this document and any and all written or oral communication(s) made by Grip or its directors, employees, associates, representatives and agents. This communication does not constitute advice relating to investing or otherwise dealing in securities and is not an offer or solicitation for the purchase or sale of any securities. Grip does not guarantee or assure any return on investments and accepts no liability for consequences of any actions taken based on the information provided. For more details, please visit www.gripinvest.in
Registered Address - 106, II F, New Asiatic Building, H Block, Connaught Place, New Delhi 110001
